Thyroid Malignancy Risk of Incidental Thyroid Nodules in Patients with Non-Thyroid Cancer

Yalcin, Mehmet Muhittin; Altınova, Alev Eroğlu; Özkan, Çiğdem; Törüner, Füsun Baloş; Aktürk, Müjde; Akdemir, Ozgur; Gedik, Tuğçe Emiroğlu; Gokce, D.; Poyraz, Aylar; Taneri, Ferit; Yetkin, İlhan

doi:10.4183/aeb.2016.185

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, thyroid gland was the most frequent site because suspicious lesions (72 out of 304) with high FDG uptake can be detected easily by visual assessment, due to the relatively low physiological FDG uptake of normal thyroid tissue. Although some benign thyroid pathologies such as thyroiditis, Grave's disease, or post-immunotherapy changes may cause increased FDG uptake, they are often diffuse in pattern, while focal hypermetabolic thyroid lesions may represent focal hyperplasia or malignancy [6,7]. Studies showed that 30.9% of focal hypermetabolic thyroid lesions are malignant, suggesting about 70% being false positive [8].…”

Section: Discussionmentioning

confidence: 99%

Retrospective study of qualitative assessment in detecting synchronous and metachronous malignancies in adult cancer patients by 18F-FDG PET/CT

Lau,

Ng,

Wong

et al. 2024

Nuclear Medicine Communications

View full text Add to dashboard Cite

Objectives The study aimed to evaluate the frequency of incidental suspicious lesions detected by flourine-18 fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) scans done for staging or restaging in adult cancer patients. We further determined the detection rate of synchronous and metachronous malignancies in these suspicious lesions after further investigations. Materials and methods This retrospective analysis evaluated the consecutive patients with 18F-FDG PET/CT scans done in Queen Elizabeth Hospital (QEH), Hong Kong between July 2021 and June 2022. The adult cancer patients who underwent staging or restaging 8F-FDG PET/CT were included while the remaining were excluded. Patients’ demographics, primary cancer type, tumor markers, and pathological analyses for the incidental suspicious lesions were reviewed to establish the detection rate of synchronous and metachronous malignancies. Results A total of 2054 patients fulfilled inclusion criteria with age ranging from 18 to 93 years old. Out of the 2054 patients, 304 (14.8%) were found to have incidental suspicious lesions. Of these, 206 patients (67.8%) underwent further investigations including pathological analyses. Subsequently, 84 of these 206 patients (40.8%) had pathologically proven synchronous or metachronous malignancies. Conclusion The detection rate of incidental suspicious lesions in adult cancer patients who underwent 18F-FDG PET/CT scans for staging or restaging was 14.8% and the rate of synchronous and metachronous malignancies in these suspicious lesions was 40.8%. The treatment plan of these patients may potentially be altered, which should be included in the cost-benefit analysis of using this imaging modality.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective study of qualitative assessment in detecting synchronous and metachronous malignancies in adult cancer patients by 18F-FDG PET/CT

Lau,

Ng,

Wong

et al. 2024

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Regarding follicular thyroid carcinomas, the molecular pathogenesis is still controversial. Oncogenic activation due to Ras point mutations is present both in follicular adenomas and carcinomas (17,19), including the oncocytic follicular carcinoma (20,21). This oncogene is involved in the cellular signal transduction and mutations induce a continuous proliferation of cells, inevitably leading to cancer.…”

Section: Discussionmentioning

confidence: 99%

Expression of Menin in the Human Thyroid Gland

et al. 2017

View full text Add to dashboard Cite

Introduction. The expression of menin in the thyroid gland has long been debated. Animal models with targeted inactivation of menin in the thyroid gland have shown that its inactivation might play a role in the progression to a more aggressive type of cancer. Human studies are conflicting, some have identified mutations in the MEN1 gene in a subtype of oncocytic thyroid carcinomas, while others have not identified a higher prevalence of thyroid cancer in MEN1 patients. Objective. To analyze the immunohistochemical expression of menin in different types of thyroid carcinomas. Materials and methods. 48 thyroid tumours (12 papillary thyroid carcinomas (PTC), 6 anaplastic thyroid carcinomas (ATC), 12 poorly differentiated thyroid carcinomas (PDTC), 5 medullary thyroid carcinomas (MTC), 5 oncocytic follicular carcinomas (OC), 3 oncocytic adenomas (OA) and 5 goiters (G)) were tested for nuclear expression of menin using an anti-menin antibody. The expression was considered positive, negative or decreased. Results. The expression of menin was positive, identical to normal tissue, in 39 cases (81.25%). The expression was decreased (n=8) or absent (n=1) in 9 tumours (18.75%-2 PTC, 5 PDTC, 2 OC) accounting for 42% (5/12) of the PDTC and 40% (2/5) of the OC. Conclusions. Our results show that the expression of menin is generally preserved in human thyroid carcinomas, but it can be decreased or absent in certain types of thyroid cancer. Further molecular studies are needed to evaluate to potential of menin protein in tumorigenesis.

show abstract